Engineers at MIT have developed injectable "mini livers" designed to support patients with severe liver disease, offering a potential alternative or temporary bridge to surgical transplants. With more than 10,000 Americans waiting for a organ donor and many too ill for major surgery, this non-invasive approach could fill a critical gap in care.
How It Works
The liver performs roughly 500 vital jobs, mostly carried out by specialized cells called hepatocytes. Instead of surgically implanting donor tissue, the MIT team created a syringe-deliverable mixture containing:
- Hepatocytes: Active liver cells that carry out core metabolic tasks.
- Hydrogel Microspheres: Tiny spheres that allow the mixture to flow as a liquid through a syringe and reform into a supportive structure inside the body.
- Fibroblasts: Helper cells that encourage new blood vessels to connect with the graft.
Using ultrasound guidance, doctors can deliver and monitor these "satellite livers" without invasive surgery.
Promising Test Results
In a study published in Cell Biomaterials, researchers injected the material into fatty abdominal tissue in mice. The results showed:
- Long-Term Survival: Cells remained viable and active for the entire eight-week study.
- Rapid Integration: Host blood vessels quickly grew into the graft to supply essential nutrients.
- Sustained Function: The cells successfully produced key proteins and enzymes normal for a healthy liver.
Clinical Potential
Because transplanted hepatocytes do not need to be attached to the host's existing liver, these grafts could be placed in other high-blood-flow areas, such as near the spleen or kidneys. Researchers envision using the technology either as a temporary boost while patients wait for a donor organ or as a long-term alternative for those unable to undergo surgery.
